With drugmakers repackaging their older medications and seeking “new rewards” for them with dozens of patents, patients are faced with increased costs as competition for lower-cost alternatives is stifled, Mr. Barrueta, SVP of government relations, wrote in a Dec. 5 statement.
To save billions in drug spending, “we first need to change laws to remove many of the patent thickets that currently threaten biosimilar development,” he said.
For example, AbbVie’s arthritis medicine Humira has more than 100 patents, and 90 percent of the 247 filed patents were submitted after the FDA authorized the drug, according to the Commonwealth Fund.
“In a world where prescription drug spending has increased 60 percent in the last decade to over $400 billion today, these anti-competitive practices are not only financially unsustainable, they’re unjust,” Mr. Barrueta wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
